Journal
NEUROSCIENCE LETTERS
Volume 487, Issue 2, Pages 169-173Publisher
ELSEVIER IRELAND LTD
DOI: 10.1016/j.neulet.2010.10.015
Keywords
Cerebrospinal fluid; Tau; Amyloid-beta; Parkinson disease; Dementia; Alzheimer disease
Categories
Funding
- Fundacio la Marato de TV3 [N-2006-TV060510]
- Fondo de Investigaciones Sanitarias [PS09/01038]
Ask authors/readers for more resources
Cerebrospinal fluid (CSF) tau and phospho-tau levels have been associated with certain tau gene variants and low CSF amyloid-beta (A beta) levels in Alzheimer disease (AD), constituting potential biomarkers of molecular mechanisms underlying neurodegeneration. We aimed to assess whether such CSF-genetic endophenotypes are also present in Parkinson disease (PD). CSF tau, phospho-tau and A beta levels were obtained from 38 PD patients (19 with dementia) using specific ELISA techniques. All cases were geno-typed for a series of tau gene polymorphisms (rs1880753, rs1880756, rs1800547, rs1467967, rs242557, rs2471738 and rs7521). The A-allele rs242557 polymorphism was the only tau gene variant significantly associated with higher CSF tau and phospho-tau levels, under both dominant and dose-response model. This association depended on the presence of dementia, and was only observed in individuals with low (<500 pg/mL) CSF A beta levels. Such genetic-CSF endophenotypes are probably a reflection of the presence of AD-like molecular changes in part of PD patients in the setting of dementia. (C) 2010 Elsevier Ireland Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available